credo DIAGNOSTICS
Knowledge Empowering People

VitaSIRO solo™

MT-RNR1 SNP Assay

A Single Nucleotide Polymorphism (SNP) in the MT-RNR1 gene, specifically m.1555A>G, is the primary cause of Aminoglycoside-Induced Hearing Loss (AIHL). This mutation can result in ototoxicity when patients receive aminoglycoside antibiotics, which are essential for treating infections, particularly in infants.

Current diagnostic methods for detecting these mutations are limited. To enhance patient safety, Credo Diagnostics Biomedical has developed the MT-RNR1 SNP Assay, delivering results in just 20 minutes. This rapid turnaround allows for timely interventions to prevent hearing loss.

Non-Invasive Sampling

Easier and faster buccal swab specimen collection

Easy Storage and Rapid Results

< 3-minute hands-on time and 20-minute turnaround time, storage under room temperature

Precision Diagnostics

High sensitivity and specificity

Diagnostic Procedure in 4 Steps:

Collect

Lyse



Transfer

Start Run





(1). The MT-RNR1 SNP Assay is validated with EMQN MT-RNR1 POCT Device Verification Sample. and we diluted the known sample by 10-fold to simulate 100 cell per swab.
(2). Wild type gene, m.1555A is not detected in all above tests.

Credo Diagnostics Biomedical Pte. Ltd.
491B River Valley Road #06-01 Valley Point Singapore 248373
service@crededxbiomed.com
crededxbiomed.com

^Version 1.0: November 2024

credo DIAGNOSTICS Knowledge Empowering People

Advanced Medical Technology for All